VERICEL CORP (NASDAQ:VCEL) was identified by our screener as a strong growth stock exhibiting a promising technical setup. The company, specializing in advanced therapies for sports medicine and severe burn care, combines solid growth fundamentals with a developing technical pattern that could signal an upward move.
Growth Fundamentals
Revenue Growth: VCEL has demonstrated strong revenue expansion, with a 14.81% increase over the past year and a 15.01% annualized growth rate over multiple years. Future revenue is projected to grow by 24.77% yearly.
Earnings Momentum: Earnings per share (EPS) surged by 400% in the last year, with an expected annual growth of 72.04% in the coming years.
Profitability: The company maintains a healthy gross margin of 72.54%, outperforming 83.15% of its biotechnology peers.
Financial Health
Balance Sheet Strength: VCEL has no debt and a strong current ratio of 5.01, indicating solid liquidity.
Solvency: The Altman-Z score of 9.81 suggests low bankruptcy risk, ranking better than 86.74% of industry competitors.
Technical Setup
Consolidation Pattern: VCEL has been trading in a range between $38.62 and $44.41, currently near the upper boundary. A breakout above $43.41 could signal further upside.
Support Levels: Multiple support zones exist between $37.91 and $42.05, providing a cushion against downward moves.
Setup Rating: The stock earns a technical setup score of 7/10, suggesting a potential entry point if resistance is breached.
While VCEL’s valuation appears high with a P/E of 1,446.67, its growth trajectory and niche market position in biotechnology justify investor interest.